Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of  casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)

Jørn Herrstedt; F. Roila; S. van Belle; R. R. Bandekar; J. Levin; S. M. Grunberg

doi:10.1093/annonc/mdn524

Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)

Jørn Herrstedt
, F. Roila
, S. van Belle
, R. R. Bandekar
, J. Levin
, S. M. Grunberg

Research output: Contribution to journal › Conference abstract in journal › Research

Original language	English
Journal	Annals of Oncology
Issue number	8
Pages (from-to)	viii 273
ISSN	0923-7534
DOIs	https://doi.org/10.1093/annonc/mdn524
Publication status	Published - 2008
Event	European Society for Medical Oncology - Stockholm, Sweden Duration: 12. Sept 2008 → 16. Sept 2008 Conference number: 33

Conference

Conference	European Society for Medical Oncology
Number	33
Country/Territory	Sweden
City	Stockholm
Period	12/09/2008 → 16/09/2008

Documents & Links

10.1093/annonc/mdn524

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Herrstedt, J., Roila, F., van Belle, S., Bandekar, R. R., Levin, J., & Grunberg, S. M. (2008). Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC). Annals of Oncology, (8), viii 273. https://doi.org/10.1093/annonc/mdn524

@article{658b58f0a02811dd9b31000ea68e967b,

title = "Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)",

author = "J{\o}rn Herrstedt and F. Roila and \{van Belle\}, S. and Bandekar, \{R. R.\} and J. Levin and Grunberg, \{S. M.\}",

note = "Volumne: 19; European Society for Medical Oncology ; Conference date: 12-09-2008 Through 16-09-2008",

year = "2008",

doi = "10.1093/annonc/mdn524",

language = "English",

pages = "viii 273",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "8",

}

Herrstedt, J, Roila, F, van Belle, S, Bandekar, RR, Levin, J & Grunberg, SM 2008, 'Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)', Annals of Oncology, no. 8, pp. viii 273. https://doi.org/10.1093/annonc/mdn524

Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC). / Herrstedt, Jørn; Roila, F.; van Belle, S. et al.
In: Annals of Oncology, No. 8, 2008, p. viii 273.

Research output: Contribution to journal › Conference abstract in journal › Research

TY - ABST

T1 - Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)

AU - Herrstedt, Jørn

AU - Roila, F.

AU - van Belle, S.

AU - Bandekar, R. R.

AU - Levin, J.

AU - Grunberg, S. M.

N1 - Conference code: 33

PY - 2008

Y1 - 2008

U2 - 10.1093/annonc/mdn524

DO - 10.1093/annonc/mdn524

M3 - Conference abstract in journal

SN - 0923-7534

SP - viii 273

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

T2 - European Society for Medical Oncology

Y2 - 12 September 2008 through 16 September 2008

ER -

Herrstedt J, Roila F, van Belle S, Bandekar RR, Levin J, Grunberg SM. Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC). Annals of Oncology. 2008;(8):viii 273. doi: 10.1093/annonc/mdn524